TransCode Therapeutics (RNAZ) Stock News
$RNAZ · NASDAQ · 1 stories in 30 days$1.78
1D +0.62%1W −5.62%1M +1.82%
BORSA has published 1 story on TransCode Therapeutics (RNAZ) in the past 30 days. BORSA’s news read on RNAZ is bullish at 69/100, −1 over 24 hours, based on 1 company event over the past 7 days. RNAZ last closed at $1.68 on Oct 13, down 5.62% over five sessions and up 1.82% over the past month. TransCode Therapeutics’ next earnings report is scheduled for Friday, Nov 13.
The wire on $RNAZ
newest first · updated · direct subject stories onlyNatera, TransCode Collaborate on Phase 2a Trial for colorectal cancer
Natera's Signatera test will identify MRD-positive patients for TransCode's Phase 2a trial of TTX-MC138 in colorectal cancer, targeting an unmet need in patients with no radiographic evidence of disease.
bullish 70 · impact 40